At the news
? BEARISHIMPACT 6/10 144 filed Apr 15, 2026 at 16:53 ET
Mark A. Goldsmith, a director and officer of Revolution Medicines, intends to sell up to 120,000 shares of common stock, valued at approximately $17.6 million, under a 10b5-1 plan. The sale is scheduled for April 15, 2026, and follows prior 10b5-1 sales by Goldsmith and affiliated trusts totaling over $4.6 million in March 2026.
- Mark A. Goldsmith is a director and officer of Revolution Medicines (RVMDW).
- He filed a Form 144 to sell up to 120,000 shares of common stock, valued at $17,641,200.
- The sale is scheduled for April 15, 2026, under a 10b5-1 plan.
- Goldsmith and affiliated trusts executed over $4.6 million in 10b5-1 sales in early March 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access